Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria
- 20 October 2015
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (5) , 1191-1193
Abstract
Rituximab-based chemoimmunotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard frontline treatment for patients with diffuse large B-cell ly...Keywords
This publication has 10 references indexed in Scilit:
- Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphomaLeukemia & Lymphoma, 2015
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II StudyJournal of Clinical Oncology, 2015
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyThe Lancet Oncology, 2014
- Using biologic predictive factors to direct therapy of diffuse large B-cell lymphomaTherapeutic Advances in Hematology, 2012
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2011
- R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.Blood, 2009
- The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cellsNature, 2004
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cellsOncogene, 2003
- Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaBlood, 2003